Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.

Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA.

BMC Cancer. 2011 Mar 28;11:112. doi: 10.1186/1471-2407-11-112.

2.

Characterization of STAT3 activation and expression in canine and human osteosarcoma.

Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA.

BMC Cancer. 2009 Mar 10;9:81. doi: 10.1186/1471-2407-9-81.

3.

Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.

Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA.

BMC Cancer. 2011 Apr 11;11:125. doi: 10.1186/1471-2407-11-125.

4.

The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.

Bill MA, Fuchs JR, Li C, Yui J, Bakan C, Benson DM Jr, Schwartz EB, Abdelhamid D, Lin J, Hoyt DG, Fossey SL, Young GS, Carson WE 3rd, Li PK, Lesinski GB.

Mol Cancer. 2010 Jun 25;9:165. doi: 10.1186/1476-4598-9-165.

5.

Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.

Bill MA, Nicholas C, Mace TA, Etter JP, Li C, Schwartz EB, Fuchs JR, Young GS, Lin L, Lin J, He L, Phelps M, Li PK, Lesinski GB.

PLoS One. 2012;7(8):e40724. doi: 10.1371/journal.pone.0040724. Epub 2012 Aug 10.

6.

Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.

Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, Termuhlen A, Gross T, Lin J.

Invest New Drugs. 2012 Jun;30(3):916-26. doi: 10.1007/s10637-011-9645-1. Epub 2011 Feb 22.

PMID:
21340507
7.

Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.

Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin J, Fuchs JR, Light E, Bradford CR, Prince ME, Carey TE.

Arch Otolaryngol Head Neck Surg. 2011 May;137(5):499-507. doi: 10.1001/archoto.2011.63.

8.

The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.

McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA.

Int J Cancer. 2009 Dec 15;125(12):2792-801. doi: 10.1002/ijc.24660.

9.

Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma.

Yan J, Wang Q, Zou K, Wang L, Schwartz EB, Fuchs JR, Zheng Z, Wu J.

Mol Med Rep. 2015 Jul;12(1):498-502. doi: 10.3892/mmr.2015.3439. Epub 2015 Mar 5.

PMID:
25760445
10.

A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.

Lin L, Deangelis S, Foust E, Fuchs J, Li C, Li PK, Schwartz EB, Lesinski GB, Benson D, Lü J, Hoyt D, Lin J.

Mol Cancer. 2010 Aug 16;9:217. doi: 10.1186/1476-4598-9-217.

11.

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.

Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ, Duan Z.

BMC Cancer. 2010 May 10;10:187. doi: 10.1186/1471-2407-10-187.

12.

Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.

Wei CC, Ball S, Lin L, Liu A, Fuchs JR, Li PK, Li C, Lin J.

Int J Oncol. 2011 Jan;38(1):279-85.

PMID:
21109950
13.

ΔNp63 mediates cellular survival and metastasis in canine osteosarcoma.

Cam M, Gardner HL, Roberts RD, Fenger JM, Guttridge DC, London CA, Cam H.

Oncotarget. 2016 Jul 26;7(30):48533-48546. doi: 10.18632/oncotarget.10406.

14.

Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.

Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, Li PK, Li C, Fuchs J, Lin J.

Cancer Res. 2010 Mar 15;70(6):2445-54. doi: 10.1158/0008-5472.CAN-09-2468. Epub 2010 Mar 9.

15.

Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.

Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA.

BMC Vet Res. 2012 Dec 17;8:244. doi: 10.1186/1746-6148-8-244.

16.

4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells in vitro and in vivo xenograft model through down-regulation of the JAK2/STAT3 pathway.

Park KR, Yun HM, Quang TH, Oh H, Lee DS, Auh QS, Kim EC.

Oncotarget. 2016 Feb 9;7(6):6960-71. doi: 10.18632/oncotarget.6873.

17.

STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH⁺/CD133⁺ stem cell-like human colon cancer cells.

Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab T, Lin J.

Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):246-51. doi: 10.1016/j.bbrc.2011.10.112. Epub 2011 Oct 31.

PMID:
22074823
18.

Impact of STAT3 inhibition on survival of osteosarcoma cell lines.

Wang X, Goldstein D, Crowe PJ, Yang JL.

Anticancer Res. 2014 Nov;34(11):6537-45.

PMID:
25368256
19.
20.

Supplemental Content

Support Center